These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 34602081)

  • 1. Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.
    Adams D; Algalarrondo V; Polydefkis M; Sarswat N; Slama MS; Nativi-Nicolau J
    Orphanet J Rare Dis; 2021 Oct; 16(1):411. PubMed ID: 34602081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
    Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M
    Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of patients with hereditary transthyretin amyloidosis - understanding the impact of management and disease progression.
    Conceição I; Coelho T; Rapezzi C; Parman Y; Obici L; Galán L; Rousseau A
    Amyloid; 2019 Sep; 26(3):103-111. PubMed ID: 31339362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis.
    Damy T; Conceição I; García-Pavía P; Gillmore J; Jandhyala R; Sabbat J; Wixner J; Coelho T
    Amyloid; 2021 Sep; 28(3):189-198. PubMed ID: 34042016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
    Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal.
    Ando Y; Waddington-Cruz M; Sekijima Y; Koike H; Ueda M; Konishi H; Ishii T; Coelho T
    Orphanet J Rare Dis; 2023 Oct; 18(1):323. PubMed ID: 37828588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary transthyretin amyloidosis overview.
    Manganelli F; Fabrizi GM; Luigetti M; Mandich P; Mazzeo A; Pareyson D
    Neurol Sci; 2022 Dec; 43(Suppl 2):595-604. PubMed ID: 33188616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus.
    Grandis M; Obici L; Luigetti M; Briani C; Benedicenti F; Bisogni G; Canepa M; Cappelli F; Danesino C; Fabrizi GM; Fenu S; Ferrandes G; Gemelli C; Manganelli F; Mazzeo A; Melchiorri L; Perfetto F; Pradotto LG; Rimessi P; Tini G; Tozza S; Trevisan L; Pareyson D; Mandich P
    Orphanet J Rare Dis; 2020 Dec; 15(1):348. PubMed ID: 33317601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
    Lyng CS; Gude E; Hodt A; Knudsen EC
    Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
    Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
    Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF; Hahn K
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.
    Gertz M; Adams D; Ando Y; Beirão JM; Bokhari S; Coelho T; Comenzo RL; Damy T; Dorbala S; Drachman BM; Fontana M; Gillmore JD; Grogan M; Hawkins PN; Lousada I; Kristen AV; Ruberg FL; Suhr OB; Maurer MS; Nativi-Nicolau J; Quarta CC; Rapezzi C; Witteles R; Merlini G
    BMC Fam Pract; 2020 Sep; 21(1):198. PubMed ID: 32967612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
    Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
    JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature.
    Dohrn MF; Auer-Grumbach M; Baron R; Birklein F; Escolano-Lozano F; Geber C; Grether N; Hagenacker T; Hund E; Sachau J; Schilling M; Schmidt J; Schulte-Mattler W; Sommer C; Weiler M; Wunderlich G; Hahn K
    J Neurol; 2021 Oct; 268(10):3610-3625. PubMed ID: 32500375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.
    Adams D; Koike H; Slama M; Coelho T
    Nat Rev Neurol; 2019 Jul; 15(7):387-404. PubMed ID: 31209302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis.
    Thimm A; Carpinteiro A; Oubari S; Papathanasiou M; Kessler L; Rischpler C; Malik RA; Herrmann K; Reinhardt HC; Rassaf T; Kleinschnitz C; Hagenacker T; Stettner M
    J Neurol; 2023 Jul; 270(7):3483-3491. PubMed ID: 37014422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.
    Adams D; Ando Y; Beirão JM; Coelho T; Gertz MA; Gillmore JD; Hawkins PN; Lousada I; Suhr OB; Merlini G
    J Neurol; 2021 Jun; 268(6):2109-2122. PubMed ID: 31907599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.
    Gillmore JD; Reilly MM; Coats CJ; Cooper R; Cox H; Coyne MRE; Green AJ; McGowan R; Moody WE; Hawkins PN
    Adv Ther; 2022 Jun; 39(6):2292-2301. PubMed ID: 35419651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.